Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.

6-month DFS by 4-to-12-week ctDNA dynamics: 98% if negative-to-negative (n=618), 100% if positive-to-negative (n=58), 59% if negative-to-positive (n=32), and 45% if positive-to-positive (n=78); HR 52.3 comparing conversion to clearance vs persistent positivity (P<0.001). Among 4-week MRD-positive patients, 12-week clearance was 57% (54/95) with adjuvant chemotherapy vs 8% (7/93) without (P<0.001). 6-month DFS in 4-week MRD-positive patients was 84% vs 34% with vs without ACT (HR 0.15, P<0.001).

ASCO Gastrointestinal Cancers Symposium 2022PubMed 36646802